Selective serotonin reuptake inhibitor and venlafaxine use in children and adolescents with major depressive disorder: A systematic review of published randomized controlled trials

Canadian Journal of Psychiatry

Volumn 49, Issue 8, 2004, Pages 557-563

  Courtney, Darren B ^a,b,c  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c Box 400 ^*  (Canada)

Author keywords

Adolescent; Antidepressive agents; Child; Depressive disorders

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

CHILD PSYCHIATRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR DEPRESSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW;

EID: 4544293525     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370404900807     Document Type: Review

References (24)

1. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 1998;37(Suppl):63S-83S.
2. Arana GW, Rosenbaum JF. Handbook of psychiatric drug therapy. Philadelphia (PA): Lippenscott Williams & Wilkins; 2000. p 86.
3. Hazell P, O'Connell D, Heathcote D, Robertson J, Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ 1995;310:897-901.
4. Food and Drug Administration: Psychopharmacologic Drugs Advisory Committee and the Anti-Infective Drugs Advisory Committee. Pediatric program summary statistics. Available: http://www.fda.gov/ohrms/dockets/ac/04/briefing/ 4006B1_04_Ped%20Exclusivity-OCD_wr_template.pdf. Accessed 2004 July 1.
5. Jenson PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke LB. Psychoactive medication prescribing practices for US children: gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry 1999;38:557-65.
6. Health Canada. Warnings/Advisories 2004. Available: http://www.hc-sc.gc. ca/english/protection/warnings/2004.htm. Accessed 2004 July 1.
7. Medicines and Healthcare products Regulatory Agency. Overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents including a summary of available safety and efficacy data. Available: http://www.mhra.gov.uk/news/2003.htm#ssri. Accessed 2004 July 1.
8. Wooltorton E. Paroxetine (Paxil, Serotax): increased risk of suicide in pediatric patients. CMAJ 2003:169;446.
9. Waechter F. Paroxetine must not be given to patients under 18. BMJ 2003;326:1282.
10. Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 2003;72:71-9.
11. Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003;60:978-82.
12. Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004;328:879-83.
13. Simeon JG, Dinicola VF, Ferguson HB, Copping W. Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry 1994;14:791-5.
14. Emslie GJ, Rush AJ, Weinburg WA, Kowatch RA, Hughes CW, Carmody T, and others. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997;54:1031-7.
15. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, and others. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002;41:1205-15.
16. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, and others. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40:762-72.
17. Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum M, and others. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003;290:1033-41.
18. Harrington R, Whitaker J, Shoebridge P, Campbell F. Systematic review of efficacy of cognitive behaviour therapies in childhood and adolescent depressive disorder. BMJ 1998;316:1559-63.
19. Mandoki MW, Tapia MR, Tapia MA, Sumner GS, Parker JL. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull 1997:33:149-54.
20. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, and others. Treatment for Adolescents With Depression Study (TADS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 2003;42:531-42.
21. Gilovich T. Something out of nothing. How we know what isn't so. New York: The Free Press; 1993. p 19-21.
22. Joffe R, Sokolov S, Streiner D. Antidepressant treatment of depression: a metaanalysis. Can J Psychiatry 1996;41:613-6.
23. Bhandari M, Busse JW, Jackowski D, Montori VM, Schünemann, Sprague S. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 2004;170:477-80.
24. Laughren T. Brief regulatory history of antidepressants and suicidality and update on current plans for analysis of pediatric suicidality data from controlled trials. Presented at joint meeting with the Anti-Infective Drugs Advisory Committee. Available: http://www.fda.gov/ohrms/dockets/ac/04/slides/ 4006s1.htm. Accessed 2004 July 1.